Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > International licensing expert Peter Turvey joins Starpharma Board

Abstract:
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the appointment of Mr Peter Turvey to the Board of Directors. Mr Turvey recently retired from CSL (ASX:CSL) as Executive Vice President Licensing for the R&D Division and Company Secretary after nearly two decades.

International licensing expert Peter Turvey joins Starpharma Board

Melbourne, Australia | Posted on March 8th, 2012

Mr Turvey brings to the Starpharma Board exceptional commercial licensing skills having worked at CSL since 1992 in various roles including Group General Counsel, Company Secretary and Executive Vice President Licensing.

Mr Turvey played a key role in the transformation of CSL from a government owned enterprise, through listing in 1994, to a global plasma and biopharmaceutical company. He led the management of CSL's intellectual property across CSL's entire operations, managing a large patent portfolio, and a global intellectual property team.

Among the many licensing deals he was involved with, the most significant included the Gardasil license to Merck & Co., the licensing of the Iscomatrix® adjuvant platform technology to the world's leading vaccine manufacturers, and establishment of the P.gingivalis vaccine technology collaboration between the CRC for Oral Health and Sanofi-Pasteur.

With a strong partnering model at the core of Starpharma's product development and with multiple products nearing market, Mr Turvey's skills and experience will be invaluable to the Board and Management of Starpharma.

Chairman of the Board, Mr Peter Bartels said: "We are very pleased to welcome Peter to the Board of Starpharma and believe his skills and experience are highly complementary to that of our existing board. We welcome Peter's experience and industry insights as we near the final stages of commercialisation for many of our products."

Mr Turvey added: "Since retiring from CSL, I was keen to remain active in a leading biopharmaceutical company and was excited and impressed at the depth and breadth of the Starpharma portfolio, the company's Management Team and significant opportunity to contribute to this business at a time where there are multiple market opportunities.

"I think the Board and Management have done a wonderful job to date to set the Company up for great success and I really look forward to contributing to that ongoing success."

Mr Turvey was appointed to the Board of AusBiotech last year and has also recently joined the Foursight Group as a Principal.

The appointment is effective from 19 March 2012.

####

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery and agrochemicals with the Company developing a number of products internally and others via commercial partnerships. In addition, products for diagnostics and laboratory reagents are already on market through licence arrangements with partners including Siemens Healthcare and Merck KGaA.

Starpharma’s lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes.

Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (TSE) to market a value-added, VivaGel® -coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Most recently Starpharma announced pre-clinical results in its Docetaxel (Taxotere®) program demonstrating significant improvements in that agent’s anticancer efficacy and the enhancement of solubility offering potential safety benefits as well. The company is also exploring dendrimer opportunities in agrochemicals in a series of industry partnerships as well as with internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

For more information, please click here

Contacts:
TOM DONOVAN
Senior Account Executive

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Appointments/Promotions/New hires/Resignations/Deaths

The National Space Society Mourns the Passing of Robert Krone, Founder of the Kepler Space Institute: Krone's Visionary and Humanistic Approach to the Study of Space Communities and Settlement Was Unique September 22nd, 2021

Leibniz Prize winner Professor Dr. Oliver G. Schmidt moves to Chemnitz University of Technology: President Professor Dr. Gerd Strohmeier refers to an 'absolute top transfer' September 10th, 2021

JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021

The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project